Triple Threat-Triple Benefit: The Rise of GLP1-GCG-FGF21 Tritagonists in Tomorrow’s Metabolic Medicine . d. 2025;3(3):43-48. Accessed February 27, 2026. https://www.thediabzen.com/index.php/d/article/view/19